loading
전일 마감가:
$0.8149
열려 있는:
$0.8
하루 거래량:
1.98M
Relative Volume:
0.31
시가총액:
$165.39M
수익:
$52.29M
순이익/손실:
$-134.84M
주가수익비율:
-1.0493
EPS:
-0.75
순현금흐름:
$-117.11M
1주 성능:
+11.54%
1개월 성능:
-6.22%
6개월 성능:
-47.53%
1년 성능:
+56.46%
1일 변동 폭
Value
$0.77
$0.8299
1주일 범위
Value
$0.70
$0.84
52주 변동 폭
Value
$0.304
$3.179

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Name
명칭
Sangamo Therapeutics Inc
Name
전화
(510) 970-6000
Name
주소
501 CANAL BLVD., RICHMOND, CA
Name
직원
183
Name
트위터
@sangamotx
Name
다음 수익 날짜
2025-03-17
Name
최신 SEC 제출 서류
Name
SGMO's Discussions on Twitter

SGMO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SGMO
Sangamo Therapeutics Inc
0.787 165.39M 52.29M -134.84M -117.11M -0.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-12-13 업그레이드 Truist Hold → Buy
2024-12-10 재확인 H.C. Wainwright Buy
2023-11-03 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2023-04-28 다운그레이드 BofA Securities Neutral → Underperform
2023-02-27 업그레이드 Wedbush Neutral → Outperform
2023-01-06 다운그레이드 BofA Securities Buy → Neutral
2022-06-13 재개 Wedbush Neutral
2021-05-04 개시 RBC Capital Mkts Outperform
2021-01-07 재개 Guggenheim Neutral
2021-01-06 개시 Stifel Hold
2020-12-16 재개 H.C. Wainwright Buy
2020-09-08 개시 BofA Securities Buy
2020-07-07 개시 SunTrust Buy
2019-08-26 개시 H.C. Wainwright Buy
2018-11-14 다운그레이드 JP Morgan Overweight → Neutral
2018-11-09 다운그레이드 Guggenheim Buy → Neutral
2018-10-10 개시 Guggenheim Buy
2018-06-20 개시 BofA/Merrill Buy
2017-11-15 업그레이드 Piper Jaffray Neutral → Overweight
2017-06-22 재개 Jefferies Buy
2016-11-01 다운그레이드 Wedbush Outperform → Neutral
2016-10-19 다운그레이드 Piper Jaffray Overweight → Neutral
2015-12-04 개시 Wells Fargo Outperform
2015-10-23 재개 Jefferies Buy
2013-05-03 개시 BioLogic Equity Research Sell
2011-02-23 재확인 JMP Securities Mkt Outperform
2010-07-29 재확인 Wedbush Outperform
2009-10-19 개시 Brean Murray Sell
2009-10-07 재확인 Leerink Swann Outperform
2009-08-25 재확인 JMP Securities Mkt Outperform
모두보기

Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스

pulisher
Apr 22, 2025

Form 4Statement of changes in beneficial ownership of securities - ADVFN

Apr 22, 2025
pulisher
Apr 15, 2025

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System - Zenopa

Apr 15, 2025
pulisher
Apr 13, 2025

Sangamo announces capsid license agreement with Eli Lilly - MSN

Apr 13, 2025
pulisher
Apr 07, 2025

Lilly, Sangamo Enter Capsid License Agreement - Contract Pharma

Apr 07, 2025
pulisher
Apr 04, 2025

Another rebound as Sangamo inks $1.4B capsid deal with Lilly - BioWorld MedTech

Apr 04, 2025
pulisher
Apr 04, 2025

Lilly Licenses Sangamo’s Capsid Technology For CNS Gene Therapy - insights.citeline.com

Apr 04, 2025
pulisher
Apr 04, 2025

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal (SGMO) - Seeking Alpha

Apr 04, 2025
pulisher
Apr 04, 2025

Sangamo Thera enters critical deal with Lilly - The Pharma Letter

Apr 04, 2025
pulisher
Apr 04, 2025

Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+ - BioSpace

Apr 04, 2025
pulisher
Apr 04, 2025

Lilly throws lifeline to Sangamo with $1.4bn licensing deal - pharmaphorum

Apr 04, 2025
pulisher
Apr 04, 2025

Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga

Apr 04, 2025
pulisher
Apr 03, 2025

RH, FIVE, SGMO, BAC, TSLA: Top 5 Trending Stocks TodayFive Below (NASDAQ:FIVE), Bank of America (NYSE:BAC) - Benzinga

Apr 03, 2025
pulisher
Apr 03, 2025

Sangamo Therapeutics (SGMO) Signs Major Licensing Deal with Eli Lilly - GuruFocus

Apr 03, 2025
pulisher
Apr 03, 2025

Sangamo Therapeutics (SGMO) Surges on Licensing Deal with Eli Li - GuruFocus

Apr 03, 2025
pulisher
Apr 03, 2025

Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal By Investing.com - Investing.com South Africa

Apr 03, 2025
pulisher
Apr 03, 2025

Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal - Investing.com Canada

Apr 03, 2025
pulisher
Apr 03, 2025

Struggling Sangamo's brain-penetrating drug delivery tech attracts Eli Lilly in potential $1.4 billion pact - The Business Journals

Apr 03, 2025
pulisher
Apr 03, 2025

Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System - MarketScreener

Apr 03, 2025
pulisher
Apr 03, 2025

Sangamo Therapeutics Stock Surges After The Bell: What's Going On? - Benzinga

Apr 03, 2025
pulisher
Apr 03, 2025

Sangamo Signs Capsid License Deal With Eli Lilly; Shares Rise After Hours - MarketScreener

Apr 03, 2025
pulisher
Apr 03, 2025

Sangamo Therapeutics stock soars on Lilly licensing deal By Investing.com - Investing.com South Africa

Apr 03, 2025
pulisher
Apr 03, 2025

Sangamo Therapeutics stock soars on Lilly licensing deal - Investing.com

Apr 03, 2025
pulisher
Apr 02, 2025

Sangamo Therapeutics, Inc. (SGMO) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

5 Best Stem Cell Companies to Invest In (April 2025) - Securities.io

Apr 02, 2025
pulisher
Mar 31, 2025

Hunter Syndrome Treatment Market Generated Opportunities, - openPR.com

Mar 31, 2025
pulisher
Mar 20, 2025

Fabry Disease Market Growth Projections 2023-2032: DelveInsight Analysis | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart

Mar 20, 2025
pulisher
Mar 20, 2025

Fabry Disease Market Growth Projections 2023-2032: - openPR

Mar 20, 2025
pulisher
Mar 19, 2025

Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Truist Removes Price Target From Sangamo Therapeutics, Keeps Buy Rating; Price Target Had Been $5 - MarketScreener

Mar 19, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - Zenopa

Mar 18, 2025
pulisher
Mar 18, 2025

8 Analysts Assess Sangamo Therapeutics: What You Need To Know - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 18, 2025
pulisher
Mar 18, 2025

US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being' - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo

Mar 18, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada

Mar 18, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus.com

Mar 18, 2025
pulisher
Mar 18, 2025

Earnings call transcript: Sangamo Therapeutics Q4 2024 reveals minor EPS miss By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 17, 2025

Sangamo: Q4 Earnings Snapshot - mySA

Mar 17, 2025
pulisher
Mar 17, 2025

Earnings call transcript: Sangamo Therapeutics Q4 2024 reveals minor EPS miss - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics Q4 2024 Earnings: EPS of -$0.11 Misses Esti - GuruFocus.com

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo: Q4 Earnings Snapshot -March 17, 2025 at 04:36 pm EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics shares fall as Q4 results miss estimates By Investing.com - Investing.com Australia

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics shares fall as Q4 results miss estimates - Investing.com India

Mar 17, 2025

Sangamo Therapeutics Inc (SGMO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
자본화:     |  볼륨(24시간):